Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cognetivity Neurosciences (CGN) has been selected as a UK delegate for Innovate UK’s Global Business Innovation Program (GBIP) visit to South Korea
  • The company’s ICA platform uses artificial intelligence and machine learning to detect early signs of cognitive impairment
  • Cognetivity’s share price was up 2.44 per cent at C$0.21, with a market cap of C$9.76 million

Cognetivity Neurosciences (CGN) has been selected for Innovate UK’s Global Business Innovation Program (GBIP) visit to South Korea.

One of fifteen companies to join the scheme, the program is aimed at innovative and globally ambitious SMEs in the digital health technology industry.

The fully funded visit takes place in March and includes five days of meetings with key contacts at medical centres and digital health companies within South Korea.

Cognetivity will also have the opportunity to attend the Korea International Medical and Hospital Equipment Show, offering further scope to benefit from pre- and post-visit support.

“It’s a privilege to have been chosen by Innovate UK from a large pool of applicants for this exciting trip. While we remain fully committed to our commercial roll-out plan closer to home, we are very interested in the prospect of piloting and deploying our Integrated Cognitive Assessment (ICA) in South Korea,” said Cognetivity CEO, Sina Habibi.

“Its healthcare system – arguably the most committed in the world to the benefits of technological innovation – represents a significant target in our long-term vision of enhancing digital diagnostics across the globe.” 

Cognetivity’s ICA platform uses artificial intelligence and machine learning to help detect early signs of cognitive impairment.

The technology tests the performance of large portions of the brain, with the potential for the early diagnosis of dementia. 

With an ageing population and increased prevalence of chronic illnesses, medical expenses in South Korea are growing at a rate of 6.8 per cent annually, as opposed to the average 2.1 per cent in other member countries of the Organisation for Economic Cooperation and Development.

Cognetivity aims to develop the ICA platform via ongoing clinical studies, with North American, European and other global markets in mind.

Shares in the company are up 2.44 per cent at C$0.21, with a market cap of C$9.76 million.

More From The Market Herald
Featured Video Play Icon

" OpSens (TSX:OPS) announces first SavvyWire procedure in the U.S.

OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.
Featured Video Play Icon

" Rapid Dose Therapeutics (CSE:DOSE) to supply leading gas and convenience store retailer

Rapid Dose (DOSE) has signed a supplier agreement with a leading gas and convenience store retailer.

" NervGen Pharma (TSXV:NGEN) announces leadership changes

NervGen Pharma Corp. (NGEN) has announced several leadership changes.